Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude de phase III pour évaluer l'inhibiteur AZD9833+ CDK4/6 dans HR+/HER2-MBC avec ESR1m détectable avant progression (SERENA-6) (SERENA-6)

22 septembre 2026 mis à jour par: AstraZeneca

Une étude de phase III, à double insu et randomisée pour évaluer le passage à AZD9833 (un SERD oral de nouvelle génération) + inhibiteur de CDK4/6 (palbociclib ou abémaciclib) vs inhibiteur continu de l'aromatase (létrozole ou anastrozole) + inhibiteur de CDK4/6 dans HR+/ Patients HER2-MBC avec mutation ESR1 détectable sans progression de la maladie pendant 1 L de traitement avec inhibiteur de l'aromatase + inhibiteur de CDK4/6 - une étude de commutation précoce guidée par l'ADNct

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

Aperçu de l'étude

Description détaillée

Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.

This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.

The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.

Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:

  • palbociclib + anastrozole
  • palbociclib + letrozole
  • abemaciclib + anastrozole
  • abemaciclib + letrozole
  • ribociclib + anastrozole
  • ribociclib + letrozole

During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.

In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.

The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.

The researchers also want to know more about how safe AZD9833 is.

The trial participants will be split into 2 groups:

  • Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
  • Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.

Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.

Type d'étude

Interventionnel

Inscription (Réel)

315

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Ansbach, Allemagne, 91522
        • Research Site
      • Augsburg, Allemagne, 86156
        • Research Site
      • Bonn, Allemagne, 53111
        • Research Site
      • Chemnitz, Allemagne, 09116
        • Research Site
      • Dresden, Allemagne, 01307
        • Research Site
      • Erlangen, Allemagne, 91054
        • Research Site
      • Essen, Allemagne, 45130
        • Research Site
      • Freiburg im Breisgau, Allemagne, 79110
        • Research Site
      • Hösbach, Allemagne, 63768
        • Research Site
      • Immenstadt im Allgäu, Allemagne, 87509
        • Research Site
      • Koblenz, Allemagne, 56068
        • Research Site
      • Leipzig, Allemagne, 4103
        • Research Site
      • Mannheim, Allemagne, 68167
        • Research Site
      • München, Allemagne, 80634
        • Research Site
      • Paderborn, Allemagne, 33098
        • Research Site
      • Ratingen, Allemagne, 40878
        • Research Site
      • Ravensburg, Allemagne, 88212
        • Research Site
      • Regensburg, Allemagne, 93053
        • Research Site
      • Stade, Allemagne, 21680
        • Research Site
      • Tübingen, Allemagne, 72076
        • Research Site
      • Ulm, Allemagne, 89075
        • Research Site
      • Birtinya, Australie, 4575
        • Research Site
      • Darlinghurst, Australie, 2010
        • Research Site
      • Leuven, Belgique, 3000
        • Research Site
      • Liège, Belgique, 4000
        • Research Site
      • Namur, Belgique, 5000
        • Research Site
      • Haskovo, Bulgarie, 6300
        • Research Site
      • Panagyurishte, Bulgarie, 4500
        • Research Site
      • Pleven, Bulgarie, 5804
        • Research Site
      • Plovdiv, Bulgarie, 4004
        • Research Site
      • Sofia, Bulgarie, 1431
        • Research Site
      • Sofia, Bulgarie, 1407
        • Research Site
      • Sofia, Bulgarie, 1527
        • Research Site
      • Sofia, Bulgarie, 1330
        • Research Site
      • Sofia, Bulgarie, 1303
        • Research Site
    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • Research Site
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Research Site
    • Quebec
      • Lévis, Quebec, Canada, G6V 3Z1
        • Research Site
      • Montreal, Quebec, Canada, H2X 0C1
        • Research Site
      • Montreal, Quebec, Canada, H3T 1E2
        • Research Site
      • Montreal, Quebec, Canada, H1T 2M4
        • Research Site
      • Québec, Quebec, Canada, G1S 4L8
        • Research Site
      • Cheonan-si, Corée du Sud, 31151
        • Research Site
      • Daegu, Corée du Sud, 42415
        • Research Site
      • Goyang-si, Corée du Sud, 10408
        • Research Site
      • Seongnam-si, Corée du Sud, 13620
        • Research Site
      • Seongnam-si, Corée du Sud, 463-712
        • Research Site
      • Seoul, Corée du Sud, 02841
        • Research Site
      • Seoul, Corée du Sud, 03080
        • Research Site
      • Seoul, Corée du Sud, 03722
        • Research Site
      • Seoul, Corée du Sud, 05505
        • Research Site
      • Seoul, Corée du Sud, 06273
        • Research Site
      • Seoul, Corée du Sud, 06351
        • Research Site
      • Seoul, Corée du Sud, 06591
        • Research Site
      • A Coruña, Espagne, 15009
        • Research Site
      • Badalona, Espagne, 08003
        • Research Site
      • Barcelona, Espagne, 8035
        • Research Site
      • L'Hospitalet de Llobregat, Espagne, 08908
        • Research Site
      • Madrid, Espagne, 28041
        • Research Site
      • Madrid, Espagne, 28040
        • Research Site
      • Murcia, Espagne, 30008
        • Research Site
      • Málaga, Espagne, 29010
        • Research Site
      • Sant Joan Despí, Espagne, 08970
        • Research Site
      • Seville, Espagne, 41013
        • Research Site
      • Valencia, Espagne, 46010
        • Research Site
      • Avignon, France, 84918
        • Research Site
      • Brest, France, 29200
        • Research Site
      • Clermont-Ferrand, France, 63050
        • Research Site
      • Dijon, France, 21079
        • Research Site
      • Limoges, France, 83000
        • Research Site
      • Lorient, France, 56322
        • Research Site
      • Lyon, France, 69373
        • Research Site
      • Marseille, France, 13273
        • Research Site
      • Metz-Tessy, France, 74370
        • Research Site
      • Nîmes, France, 30029
        • Research Site
      • Paris, France, 75248
        • Research Site
      • Rouen, France, 76021
        • Research Site
      • Saint-Cloud, France, 92210
        • Research Site
      • Saint-Herblain, France, 44805
        • Research Site
      • Toulouse, France, 31100
        • Research Site
      • Tours, France, 37000
        • Research Site
      • Vandœuvre-lès-Nancy, France, 54519
        • Research Site
      • Vantoux, France, 57070
        • Research Site
      • Villejuif, France, 94805
        • Research Site
      • Budapest, Hongrie, 1122
        • Research Site
      • Budapest, Hongrie, 1062
        • Research Site
      • Miskolc, Hongrie, 3526
        • Research Site
      • Szekszárd, Hongrie, 7100
        • Research Site
      • Szolnok, Hongrie, 5000
        • Research Site
      • Zalaegerszeg, Hongrie, 8900
        • Research Site
      • Beersheba, Israël, 8410101
        • Research Site
      • Haifa, Israël, 3109601
        • Research Site
      • Jerusalem, Israël, 91120
        • Research Site
      • Petah Tikva, Israël, 494142
        • Research Site
      • Ramat Gan, Israël, 5262000
        • Research Site
      • Bergamo, Italie, 24127
        • Research Site
      • Bologna, Italie, 40138
        • Research Site
      • Florence, Italie, 50134
        • Research Site
      • Meldola, Italie, 47014
        • Research Site
      • Milan, Italie, 20141
        • Research Site
      • Milan, Italie, 20132
        • Research Site
      • Misterbianco, Italie, 95045
        • Research Site
      • Naples, Italie, 80131
        • Research Site
      • Padova, Italie, 35128
        • Research Site
      • Roma, Italie, 00168
        • Research Site
      • Rozzano, Italie, 20089
        • Research Site
      • Chiba, Japon, 260-8717
        • Research Site
      • Chūōku, Japon, 104-0045
        • Research Site
      • Hidaka-shi, Japon, 350-1298
        • Research Site
      • Hirakata-shi, Japon, 573-1191
        • Research Site
      • Kitaadachi-gun, Japon, 362-0806
        • Research Site
      • Kumamoto, Japon, 860-8556
        • Research Site
      • Kōtoku, Japon, 135-8550
        • Research Site
      • Matsuyama, Japon, 791-0280
        • Research Site
      • Nagoya, Japon, 464-8681
        • Research Site
      • Nagoya, Japon, 467-8602
        • Research Site
      • Niigata, Japon, 951-8566
        • Research Site
      • Osaka, Japon, 540-0006
        • Research Site
      • Osaka, Japon, 541-8567
        • Research Site
      • Ota-shi, Japon, 373-8550
        • Research Site
      • Sapporo, Japon, 003-0804
        • Research Site
      • Shinagawa-ku, Japon, 142-8666
        • Research Site
      • Shinjuku-ku, Japon, 162-8655
        • Research Site
      • Takasaki-shi, Japon, 370-0829
        • Research Site
      • Takatsuki-shi, Japon, 569-8686
        • Research Site
      • Tsukuba, Japon, 305-8577
        • Research Site
      • Yokohama, Japon, 241-8515
        • Research Site
      • Graz, L'Autriche, 8036
        • Research Site
      • Innsbruck, L'Autriche, 6020
        • Research Site
      • Salzburg, L'Autriche, 5020
        • Research Site
      • Vienna, L'Autriche, 1130
        • Research Site
      • Guimarães, Le Portugal, 4835-044
        • Research Site
      • Lisbon, Le Portugal, 1649-035
        • Research Site
      • Lisbon, Le Portugal, 1400-038
        • Research Site
      • Lisbon, Le Portugal, 1500-650
        • Research Site
      • Lisbon, Le Portugal, 1449-005
        • Research Site
      • Loures, Le Portugal, 2674-514
        • Research Site
      • Porto, Le Portugal, 4099-001
        • Research Site
      • Porto, Le Portugal, 4200-319
        • Research Site
      • Porto, Le Portugal, 4200-072
        • Research Site
      • Vila Nova de Gaia, Le Portugal, 4434-502
        • Research Site
      • Drammen, Norvège, 3004
        • Research Site
      • Oslo, Norvège, 0450
        • Research Site
      • Bydgoszcz, Pologne, 85-796
        • Research Site
      • Gdynia, Pologne, 81-519
        • Research Site
      • Koszalin, Pologne, 75-581
        • Research Site
      • Lodz, Pologne, 90-302
        • Research Site
      • Poznan, Pologne, 60-693
        • Research Site
      • Rzeszów, Pologne, 35-001
        • Research Site
      • Tomaszów Mazowiecki, Pologne, 97-200
        • Research Site
      • Warsaw, Pologne, 02-781
        • Research Site
      • Blackpool, Royaume-Uni, FY3 8NR
        • Research Site
      • Cambridge, Royaume-Uni, CB2 0QQ
        • Research Site
      • London, Royaume-Uni, SW3 6JJ
        • Research Site
      • London, Royaume-Uni, WC1N 3BG
        • Research Site
      • Manchester, Royaume-Uni, M20 4BX
        • Research Site
      • Newport, Royaume-Uni, NP10 8FZ
        • Research Site
      • Nottingham, Royaume-Uni, NG5 1PB
        • Research Site
      • Portsmouth, Royaume-Uni, PO6 3LY
        • Research Site
      • Reading, Royaume-Uni, RG2 9LH
        • Research Site
      • Sheffield, Royaume-Uni, S10 2SJ
        • Research Site
      • Sutton, Royaume-Uni, SM2 5PT
        • Research Site
      • Taunton, Royaume-Uni, TA1 5DA
        • Research Site
      • Moscow, Russie, 111123
        • Research Site
      • Moscow, Russie, 143423
        • Research Site
      • Moscow, Russie, 129090
        • Research Site
      • Nizhny Novgorod, Russie, 603126
        • Research Site
      • Podolsk, Russie, 142100
        • Research Site
      • Saint Petersburg, Russie, 197758
        • Research Site
      • Saint Petersburg, Russie, 194017
        • Research Site
      • Banská Bystrica, Slovaquie, 974 01
        • Research Site
      • Bratislava, Slovaquie, 833 01
        • Research Site
      • Košice, Slovaquie, 041 91
        • Research Site
      • Michalovce, Slovaquie, 07101
        • Research Site
      • Partizánske, Slovaquie, 958 01
        • Research Site
      • Bern, Suisse, CH-3010
        • Research Site
      • Chur, Suisse, CH-7000
        • Research Site
      • Winterthur, Suisse, 8401
        • Research Site
      • Kaohsiung City, Taïwan, 833
        • Research Site
      • Taichung, Taïwan, 40705
        • Research Site
      • Tainan, Taïwan, 70403
        • Research Site
      • Tainan, Taïwan, 710
        • Research Site
      • Taipei, Taïwan, 100
        • Research Site
      • Taipei, Taïwan
        • Research Site
      • Taipei, Taïwan, 11490
        • Research Site
      • Taipei, Taïwan, 23561
        • Research Site
      • Taipei, Taïwan, 11259
        • Research Site
      • Taipei, Taïwan, 110
        • Research Site
      • Taoyuan, Taïwan, 333
        • Research Site
      • Adana, Turquie (Türkiye), 01120
        • Research Site
      • Ankara, Turquie (Türkiye), 06100
        • Research Site
      • Ankara, Turquie (Türkiye), 06520
        • Research Site
      • Ankara, Turquie (Türkiye), 06010
        • Research Site
      • Ankara, Turquie (Türkiye), 06340
        • Research Site
      • Cordaleo, Turquie (Türkiye), 35575
        • Research Site
      • Izmir, Turquie (Türkiye), 35100
        • Research Site
      • Izmir, Turquie (Türkiye), 35360
        • Research Site
      • Kadıkoy/Istanbul, Turquie (Türkiye), 34722
        • Research Site
      • Kayseri, Turquie (Türkiye), 38039
        • Research Site
    • Arizona
      • Phoenix, Arizona, États-Unis, 85054
        • Research Site
    • Arkansas
      • Hot Springs, Arkansas, États-Unis, 71913
        • Research Site
      • Little Rock, Arkansas, États-Unis, 72205
        • Research Site
    • California
      • Long Beach, California, États-Unis, 90806
        • Research Site
      • San Diego, California, États-Unis, 92123
        • Research Site
      • Santa Rosa, California, États-Unis, 92805
        • Research Site
    • Colorado
      • Grand Junction, Colorado, États-Unis, 81501
        • Research Site
      • Lone Tree, Colorado, États-Unis, 80124
        • Research Site
    • Florida
      • Fort Myers, Florida, États-Unis, 33901
        • Research Site
      • Jacksonville, Florida, États-Unis, 32256
        • Research Site
      • Jacksonville, Florida, États-Unis, 32224
        • Research Site
      • St. Petersburg, Florida, États-Unis, 33705
        • Research Site
    • Georgia
      • Atlanta, Georgia, États-Unis, 30318
        • Research Site
      • Atlanta, Georgia, États-Unis, 30322
        • Research Site
      • Atlanta, Georgia, États-Unis, 30342
        • Research Site
    • Illinois
      • Park Ridge, Illinois, États-Unis, 60068
        • Research Site
    • Indiana
      • Fort Wayne, Indiana, États-Unis, 46804
        • Research Site
      • Indianapolis, Indiana, États-Unis, 46250
        • Research Site
    • Maryland
      • Baltimore, Maryland, États-Unis, 21202
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Research Site
      • Fairhaven, Massachusetts, États-Unis, 02719
        • Research Site
      • Foxborough, Massachusetts, États-Unis, 02035
        • Research Site
      • Milford, Massachusetts, États-Unis, 01757
        • Research Site
      • South Weymouth, Massachusetts, États-Unis, 02190
        • Research Site
    • Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Research Site
      • Grand Rapids, Michigan, États-Unis, 49503
        • Research Site
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Research Site
    • Mississippi
      • Oxford, Mississippi, États-Unis, 38655
        • Research Site
    • Missouri
      • Kansas City, Missouri, États-Unis, 64111
        • Research Site
      • St Louis, Missouri, États-Unis, 63110
        • Research Site
    • Montana
      • Billings, Montana, États-Unis, 59101
        • Research Site
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68130
        • Research Site
    • New Jersey
      • Camden, New Jersey, États-Unis, 08103
        • Research Site
      • Ridgewood, New Jersey, États-Unis, 07450
        • Research Site
    • New York
      • Brooklyn, New York, États-Unis, 11215
        • Research Site
      • East Syracuse, New York, États-Unis, 13057
        • Research Site
      • New Hyde Park, New York, États-Unis, 11042
        • Research Site
      • New York, New York, États-Unis, 10065
        • Research Site
      • New York, New York, États-Unis, 11355
        • Research Site
      • Shirley, New York, États-Unis, 11967
        • Research Site
    • North Carolina
      • Goldsboro, North Carolina, États-Unis, 27534
        • Research Site
    • Ohio
      • Canton, Ohio, États-Unis, 44710
        • Research Site
      • Cincinnati, Ohio, États-Unis, 45220
        • Research Site
      • Columbus, Ohio, États-Unis, 43219
        • Research Site
    • Oregon
      • Portland, Oregon, États-Unis, 97213
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Research Site
      • Pittsburgh, Pennsylvania, États-Unis, 15213
        • Research Site
      • York, Pennsylvania, États-Unis, 17403
        • Research Site
    • South Carolina
      • Greenville, South Carolina, États-Unis, 29607
        • Research Site
      • West Columbia, South Carolina, États-Unis, 29169
        • Research Site
    • Tennessee
      • Knoxville, Tennessee, États-Unis, 37916
        • Research Site
      • Memphis, Tennessee, États-Unis, 38120
        • Research Site
      • Nashville, Tennessee, États-Unis, 37203
        • Research Site
    • Texas
      • Bedford, Texas, États-Unis, 76022
        • Research Site
      • Dallas, Texas, États-Unis, 75246
        • Research Site
      • Houston, Texas, États-Unis, 77030
        • Research Site
      • Houston, Texas, États-Unis, 77024
        • Research Site
      • Longview, Texas, États-Unis, 75601
        • Research Site
      • San Antonio, Texas, États-Unis, 78240
        • Research Site
    • Utah
      • Salt Lake City, Utah, États-Unis, 84106
        • Research Site
    • Virginia
      • Midlothian, Virginia, États-Unis, 23114
        • Research Site
      • Norfolk, Virginia, États-Unis, 23502
        • Research Site
    • Washington
      • Tacoma, Washington, États-Unis, 98405
        • Research Site
    • Wisconsin
      • Waukesha, Wisconsin, États-Unis, 53226
        • Research Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 130 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

INCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:

  • Have advanced breast cancer that is not able to be treated with surgery or radiation;
  • Have an ESR1 mutation in their cancer;
  • Have breast cancer that is HR-positive and HER2-negative;
  • Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
  • Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
  • Are able to do their daily activities;
  • Are at least 18.

Full list of inclusion criteria:

  • Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
  • Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
  • Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
  • Eastern Cooperative Oncology Group performance status of 0 or 1;
  • ESR1m detected by central testing of ctDNA with Guardant360® CDx;
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
  • Adequate organ and marrow function.

EXCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:

  • Had certain types of tumors in the past that may come back;
  • Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
  • Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.

Full list of exclusion criteria:

  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
  • Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
  • Patient with known or family history of severe heart disease;
  • Previous treatment with AZD9833, investigational SERDs or fulvestrant;
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
  • Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: AZD9833 + palbociclib, abemaciclib or ribociclib

The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)

Dosage formulation: AZD9833 tablets will be administered orally

Dosage formulation: anastrozole placebo tablets will be administrated orally.

Dosage formulation: letrozole placebo tablets will be administered orally.

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

Comparateur actif: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib

The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

Dosage formulation: AZD9833 placebo tablets will be administrated orally.

Dosage formulation: anastrozole tablets will be administered orally.

Dosage formulation: letrozole tablets will be administered orally.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
Délai: From randomization until the earlier of the progression event or death (approximately 2 years)

PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.

From randomization until the earlier of the progression event or death (approximately 2 years)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-free survival 2 (PFS2)
Délai: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)

PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
Overall survival (OS)
Délai: From randomization until the date of death due to any cause (approximately 5 years)

The OS is defined as the time from randomization to death due to any cause.

From randomization until the date of death due to any cause (approximately 5 years)
Chemotherapy free survival
Délai: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)

Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.

From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
Délai: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)

ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1.

From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
Clinical benefit rate at 24 weeks (CBR24)
Délai: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)

CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment)

At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
Change from baseline in EORTC QLQ-C30 scale scores
Délai: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Change from baseline in EORTC QLQ-BR23 scale scores
Délai: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Plasma concentration of AZD9833 at specified timepoints
Délai: on Day 15 for each patient

To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.

on Day 15 for each patient

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

30 juin 2021

Achèvement primaire (Réel)

30 juin 2025

Achèvement de l'étude (Estimé)

1 septembre 2028

Dates d'inscription aux études

Première soumission

30 juin 2021

Première soumission répondant aux critères de contrôle qualité

14 juillet 2021

Première publication (Réel)

16 juillet 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

22 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Délai de partage IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Critères d'accès au partage IPD

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner